Zoetis’ 2026 Q2 Earnings Call: Pricing Strategy Shifts, Accelerating Competition, and Worsening Affordability Outlook

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $2.5B, flat reported, down 1% organic operational
• EPS: $1.87 per diluted share
• Gross Margin: 72.9%, down 40 bps reported, up 10 bps ex-FX

Guidance:

• Revenue growth expected to decline 3% to 1% YOY on an organic operational basis.
• Adjusted net income expected to decline 9% to 5% YOY on an organic operational basis.
• Adjusted diluted EPS expected to be $5.65 to $6.55, down from prior guidance.

Business Commentary:

Companion Animal Market Challenges:

• Zoetis reported that companion animal revenue declined 6% in the second quarter, with specific pressures in dermatology, parasiticides, and OA pain segments.
• The decline was driven by reduced clinic visits, more selective pet owner purchasing, and increased competitive pressures, including higher discounting and promotional activities by new entrants.

Livestock and Diagnostics Strength:

• The livestock segment achieved an 11% revenue increase in the second quarter, supported by strong demand in cattle and poultry.
• This growth was attributed to favorable producer economics, improved product supply, and the ongoing demand for Zoetis's broad portfolio of medicines and vaccines.

U.S. Market Performance:

• U.S. companion animal revenue decreased by 11%, impacted by declining clinic traffic and affordability concerns among pet owners.
• The U.S. market was affected by intense competition and promotional activities in key franchises, alongside broader economic pressures influencing consumer spending.

Guidance Revision and Strategic Response:

• Zoetis revised its full-year revenue guidance to reflect the current operating environment, now expecting a 3% to 1% decline year-on-year.
• The revision is due to ongoing competitive and pricing pressures, particularly in the U.S. companion animal segment, alongside persistent macroeconomic headwinds.

Leadership and Organizational Changes:

• Zoetis announced leadership changes, including the promotion of Abe Nayak and the appointment of Jay Zakara as CFO and COO.
• These changes are aimed at enhancing decision-making speed, organizational agility, and aligning the company's structure to better navigate the current competitive landscape.

Sentiment Analysis:

Overall Tone: Negative

• Management stated results 'fell short of our expectations' and are 'operating in a more competitive and value-conscious environment.' They revised guidance lower due to 'continued pressure across U.S. companion animal categories' and noted 'we are not assuming the market gets easier.'

Q&A:

• Question from Erin Wright (Morgan Stanley): Concerns about targeted price actions, net price realization, primary stabilization levers, timing, dollar share loss assumptions in guidance, and organizational stability/leadership changes.
  Response: Focus is on growth-to-net ( targeted, temporary investments at point-of-sale to protect volume/share, not lowering permanent list prices. Guidance assumes persistence of softer demand and competitive pressures, with actions accelerating in second half. Leadership changes are about building the right team for execution.

• Question from Brandon Vasquez (William Blair): Clarification on gross-to-net pricing and its margin impact, and comparison of updated vs. old guidance.
  Response: Gross-to-net refers to temporary promotional actions (e.g., rebates, bundling) to protect share, not permanent list price reductions. Updated guidance reflects higher macro/competitive pressure (low end assumes acceleration), with ~$60-65M FX headwind on revenue and ~$30M on bottom line.

• Question from Michael Riskin (Bank of America): Details on cost actions beyond price, and outlook on competitive landscape exiting 2026.
  Response: Taking commercial execution and cost management actions (e.g., SG&A down 4% YOY in Q2, lower manufacturing costs). Not providing 2027 guidance, but new U.S. competitor in dermatology will keep share under pressure; focus is on defending portfolio (APOQUEL, Cytopoint) and managing affordability.

• Question from Dave Westenberg (Piper Sandler): Quantification of Q2 deterioration (macro vs. competitive), and prudence in guidance regarding rebates/contracts.
  Response: Both macro (e.g., clinic visit declines) and competitive factors were meaningfully impactful in Q2, converging in a slow growth market. Guidance incorporates prudence; promotional actions are customer/contract specific (typically 2-3 year terms), making precise public quantification difficult.

• Question from Chris Schott (JP Morgan): Duration of promotional initiatives and realistic livestock growth for second half.
  Response: Promotional intensity varies by category (dermatology more competitive, parasiticides more macro). Signs of stabilization would be share/volume stabilization and reduced growth-to-net investments. Livestock fundamentals remain strong; Q2 U.S. growth of 23% moderated from transitory drivers, expecting normalized high-single-digit growth in second half.

• Question from John Block (Stiefel): Update on 2026 price realization, and whether promotional actions are limited to dermatology or include parasiticides.
  Response: Price realization expected in range of 0% to -1% (potentially -2% at low end of guidance) due to competitive responses. Promotions are in both dermatology (mainly) and parasiticides (U.S.), with cross-portfolio bundling; focused on defending share and value amid affordability pressures.

• Question from Daniel Gross (Citi): Changes to marketing/channel strategy and ROI of direct-to-consumer (DTC) investment.
  Response: DTC advertising at retail (e.g., Google, online sites) delivers high ROI by converting already interested pet owners. Strategy remains focused on this high-impact, short-term conversion versus longer-term market growth investments.

Contradiction Point 1

Nature and Impact of Competitive Pricing Actions

Contradiction on whether price actions are temporary or permanent and their effect on list prices.

Brandon Vasquez (William Blair) - Brandon Vasquez (William Blair)

2026Q2: Gross-to-net pricing refers to temporary promotional and rebate actions... not a permanent lowering of list prices or ASPs. - Kristen Peck(CEO)

How does gross-to-net pricing impact ASPs and margins, and what are the key changes in the updated full-year guidance compared to the previous one? - Navann Ty (BNP Paribas)

2026Q1: Pricing strategies are tailored by market/product... aggregate price expectation is now 1%-2% (down from 2%-3% start of year). Competitors are raising list prices but still operate below Zoetis's list prices, though the gap is closing. - Wetteny Joseph(CFO)

Contradiction Point 2

Outlook for Competitive Intensity and Pricing in 2026

Guidance shifts from expecting controlled competition to anticipating its persistence and acceleration.

Can you discuss William Blair's recent earnings performance and future outlook? - Brandon Vasquez (William Blair)

2026Q2: The updated guidance assumes the persistence and potential acceleration of current macro and competitive pressures. - Whitney Joseph(CFO)

Can you clarify what "gross-to-net pricing" means for ASPs and margins and compare the updated full-year guidance to the previous guidance, highlighting key changes? - Christopher LoBianco (TD Cowen)

2025Q4: Competitive pressure on Trio has been limited so far. There is significant remaining market expansion... - Wetteny Joseph(CFO)

Contradiction Point 3

Macroeconomic Environment and Pet Owner Affordability

The assessment of the macro environment for pet owners shifts from expecting improvement to acknowledging worsening affordability pressures.

What questions did Michael Riskin from Bank of America raise during the earnings call? - Michael Riskin (Bank of America)

2026Q2: The updated guide assumes... affordability challenges. - Kristen Peck(CEO)

What cost controls beyond pricing are being implemented, what impact are they expected to have in H2, what assumptions underpin the competitive landscape exiting 2026, and is growth possible in 2027? - Brandon Vazquez (William Blair)

2025Q4: The macro environment for pet owners is expected to improve through 2026. - Kristin Peck(CEO)

Contradiction Point 4

Price Contribution and Realization Outlook

The guidance for price contribution shifts from positive to negative, reflecting changing competitive pressures.

John Block (Stiefel) - John Block (Stiefel)

2026Q2: Price was approximately flat in Q2. The full-year expectation is now a range of 0% to -1% (potentially -2% at the low end of guidance) due to competitive pricing actions. - Whitney Joseph(CFO)

Could you provide an update on the 2026 price realization guidance, clarify whether promotions extend beyond Dermatology to Parasiticides, and confirm if the product portfolio remains sufficiently differentiated to compete effectively? - Erin Wright (Morgan Stanley)

2025Q3: Factors supporting future growth include: typical 2-4% price contribution (currently near 4%). - Wetteny Joseph(CFO)

Contradiction Point 5

Primary Driver of U.S. Dermatology Performance

The stated cause for dermatology weakness shifts from macro/visit pressure to direct competitive product headwinds.

Dave Westenberg (Piper Sandler) - Dave Westenberg (Piper Sandler)

2026Q2: The decline in therapeutic visits for derm... Competitive positioning is not significantly different from expectations, with limited patient share gains. - Wetteny Joseph(CFO) [from 2025Q3-5]

Quantify how much of Q2 revenue deterioration was due to macro (visitation) vs. competitive (ASP) headwinds, and how should investors think about rebate changes given typical 2-year contracts? - Christopher Schott (JPMorgan)

2026Q2: Cytopoint headwinds were largely macro... Dermatology and Simperica are competitive areas where Zoetis is facing pressure. - Whitney Joseph(CFO)